Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal
Durban, KwaZulu-Natal, 4013, South Africa
NCT Number: NCT04341779
This study seeks to determine the clinical efficacy and cost effectiveness of implementing an integrated model for HIV monitoring using point of care (POC) tenofovir (TFV) adherence testing and POC viral load (VL) monitoring in improving ART adherence, maintaining durable VL suppression, and improving retention in care among HIV-positive individuals initiating first-line tenofovir disoproxil fumarate (TDF)-based ART in South Africa.
This study is active but is not currently recruiting participants.
Notify Me16 year and older
All sexes
Interventional
Not applicable
Durban, KwaZulu-Natal, 4013, South Africa
This study will be a two-arm, open-label, randomized controlled superiority trial at an HIV clinic in Durban. HIV-positive individuals aged 16 years and above, who are initiating a tenofovir-based, first-line ART will be randomized to receive POC VL testing and POC TFV adherence testing, versus standard-of-care (SoC) viral load testing. The schedule for VL testing and management of VL test results will follow South African guidelines for HIV VL testing after ART initiation. 540 participants will be randomized (1:1) at ART initiation into the intervention arm (routine POC TFV adherence testing with POC VL monitoring) or the standard-of-care (SoC) arm (no objective TFV adherence testing and SoC VL monitoring).
Participants will be followed to compare concentrations between study arms at 24 weeks after ART initiation and a composite outcome of VL suppression and retention in care between the study arms at 72 weeks after ART initiation. The study will use process evaluation data, interviews and focus groups with patients and staff to assess implementation of the POC assays. Micro-costing will be conducted to estimate intervention costs.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Point-of-care testing of HIV viral load and tenofovir, and providing same day results to participants
Time frame: 72 weeks after ART initiation
We will measure viral load by a laboratory-based reference assay, performed by the South African National Health Laboratory Services. Viral suppression will be defined as a viral load <200 copies/mL. This outcome will also include retention in care.
Time frame: 72 weeks after ART initiation
We will measure tenofovir-diphosphate concentrations in 3mm dried blood spots using liquid chromatography/tandem mass spectrometry.
Time frame: 24 and 72 weeks after ART initiation
We will assess acceptability of point-of-care tenofovir and viral load testing by conducting semi-structured in-depth interviews and focus group discussions with study participants.
Time frame: 24 and 72 weeks after ART initiation
We will conduct a micro-costing of the costs associated with point-of-care tenofovir and viral load testing and will estimate the cost-effectiveness of the intervention using an existing individual-based, stochastic HIV model for KwaZulu-Natal for simulating health and economic outcomes.
University of Washington
Other
Simplifying Treatment and Monitoring for HIV (STREAM HIV): Point-of-Care Urine Tenofovir Adherence and Viral Load Testing to Improve HIV Outcomes in South Africa
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03729778
Acquired Immunodeficiency Syndrome, Bacterial Infections
Aurora, Colorado, United States
View Trial DetailsNCT06036238
Acquired Immunodeficiency Syndrome, Alcohol Drinking
Mbita, Kenya
View Trial DetailsNCT04176172
Acquired Immunodeficiency Syndrome, Behavior
Chicago, Illinois, United States
View Trial DetailsNCT06347146
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Masaka, Uganda
View Trial Details